Bio­gen CEO seeks 'aw­ful lot more col­lab­o­ra­tions' to beef up R&D as it launch­es post­par­tum de­pres­sion, Alzheimer's and ALS drugs

Bio­gen CEO Chris Viehbach­er said the famed Boston biotech is ready to do “an aw­ful lot more col­lab­o­ra­tions” as it seeks to fill out its ear­ly-stage R&D work, but he doesn’t an­tic­i­pate any more big ac­qui­si­tions in the near term as it di­gests the $7.3 bil­lion pur­chase of rare dis­ease drug­mak­er Rea­ta Phar­ma­ceu­ti­cals, its first M&A for­ay in four years.

Speak­ing to re­porters Wednes­day morn­ing ahead of Bio­gen’s third-quar­ter up­date, Viehbach­er said the com­pa­ny was ahead of con­sen­sus with three-month rev­enues of $2.53 bil­lion, but that’s not what in­vestors and an­a­lysts are fo­cused on. “The street isn’t re­al­ly think­ing about the re­sults that we’re achiev­ing to­day,” he said. “They’re re­al­ly think­ing about where’s Bio­gen go­ing and when does it re­turn to growth.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER